Teva Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries (TEVA), announced that the European Commission has granted marketing authorizations for its two denosumab biosimilar candidates PONLIMSI, a biosimilar to Prolia and DEGEVMA, a biosimilar to Xgeva. Teva plans to launch both products in key European markets in the coming months.
Steffen Nock, SVP Head of Biosimilars & Chief Science Officer, said: "This approval represents an important step forward in increasing patient access to biosimilar therapies for serious bone conditions."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.